<DOC>
	<DOCNO>NCT00701805</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety paricalcitol injection . Subjects administer clinical supply 3 time week , 40 week dialysis session dose-titration manner , follow 12 week treatment dose-response study , M10-309 ( NCT00667576 ) .</brief_summary>
	<brief_title>Long-term Safety Study Paricalcitol Injection Chronic Kidney Disease Patients With Hemodialysis ( HD )</brief_title>
	<detailed_description>The first 12-week period study dose-response study report Study M10-309 ( NCT00667576 ) . Only subject complete 12 week NCT00667576 enrol study ( M10-312 ) . Baseline study Baseline NCT00667576 . The duration treatment Study M10-312 40 week ( total 52 week , include NCT00667576 ) .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Patients complete 12 week Study M10309 ( NCT00667576 ) . Patients take drug affect intact parathyroid hormone ( iPTH ) , calcium , bone metabolism . Patients progressive malignancy clinically significant hepatic disease . Patients develop severe cerebrovascular/cardiovascular disease doseresponse portion study ( i.e. , M10309 , NCT00667576 ) . Patients uncontrolled diabetes doseresponse portion study ( i.e. , M10309 , NCT00667576 ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Secondary hyperparathyroidism</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>paricalcitol</keyword>
</DOC>